| dbo:abstract |
Roxadustat ist ein (HIF-PHI), der die Produktion von Hämoglobin und Erythrozyten stimuliert. Er wird als Arzneistoff zur oralen Behandlung der Anämie („Blutarmut“) infolge einer chronischen Nierenerkrankung (CKD) verwendet. (de) Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD). It is taken by mouth. The drug was developed by FibroGen, in partnership with AstraZeneca. The most common side effects include hypertension (high blood pressure), vascular access thrombosis (formation of blood clots in the blood vessels associated with dialysis), diarrhea, peripheral edema (swelling especially of the ankles and feet), hyperkalemia (high blood potassium levels) and nausea (feeling sick). Roxadustat received its first global approval in China on 17 December 2018, for the treatment of anemia caused by CKD in patients who are dialysis-dependent. It was approved in Japan in 2019, for the treatment of anemia caused by CKD in patients on dialysis, and in 2020 for patients not on dialysis. Roxadustat was approved for medical use in the European Union in August 2021. (en) |
| dbo:alternativeName |
Evrenzo (en) |
| dbo:casNumber |
808118-40-3 |
| dbo:drugbank |
DB04847 |
| dbo:fdaUniiCode |
X3O30D9YMX |
| dbo:kegg |
D10593 |
| dbo:pubchem |
11256664 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Roxadustat.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/roxadustat |
| dbo:wikiPageID |
55979415 (xsd:integer) |
| dbo:wikiPageLength |
13508 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1119603687 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Pulmonary_hypertension dbr:Hyperkalemia dbr:Hypertension dbr:Peripheral_edema dbc:Acetic_acids dbr:Nausea dbr:Oral_administration dbr:Anemia dbr:Simona_Halep dbr:Performance-enhancing_drugs dbr:HIF_prolyl-hydroxylase_inhibitor dbr:2022_US_Open_–_Women's_singles dbr:Erythropoietin dbr:Chronic_kidney_disease dbr:Diarrhea dbr:Red_blood_cell dbc:AstraZeneca_brands dbr:Hemoglobin dbc:Isoquinolines dbr:AstraZeneca dbr:VEGF dbc:Diaryl_ethers dbr:Athletic_doping |
| dbp:atcPrefix |
B03 (en) |
| dbp:atcSuffix |
XA05 (en) |
| dbp:c |
19 (xsd:integer) |
| dbp:casNumber |
808118 (xsd:integer) |
| dbp:chemspiderid |
9431690 (xsd:integer) |
| dbp:drugbank |
DB04847 (en) |
| dbp:h |
16 (xsd:integer) |
| dbp:iupacName |
2 (xsd:integer) |
| dbp:kegg |
D10593 (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:licenceEu |
yes (en) |
| dbp:n |
2 (xsd:integer) |
| dbp:o |
5 (xsd:integer) |
| dbp:pubchem |
11256664 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:smiles |
CC1=NCCNCCO (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
YOZBGTLTNGAVFU-UHFFFAOYSA-N (en) |
| dbp:synonyms |
FG-4592, ASP1517, AZD9941 (en) |
| dbp:tradename |
Evrenzo (en) |
| dbp:unii |
X3O30D9YMX (en) |
| dbp:width |
250 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_journal dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Antianemic_preparations dbt:AstraZeneca |
| dcterms:subject |
dbc:Acetic_acids dbc:AstraZeneca_brands dbc:Isoquinolines dbc:Diaryl_ethers |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Roxadustat ist ein (HIF-PHI), der die Produktion von Hämoglobin und Erythrozyten stimuliert. Er wird als Arzneistoff zur oralen Behandlung der Anämie („Blutarmut“) infolge einer chronischen Nierenerkrankung (CKD) verwendet. (de) Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD). It is taken by mouth. The drug was developed by FibroGen, in partnership with AstraZeneca. (en) |
| rdfs:label |
Roxadustat (de) Roxadustat (en) |
| owl:sameAs |
wikidata:Roxadustat dbpedia-de:Roxadustat dbpedia-ro:Roxadustat https://global.dbpedia.org/id/2Y6Lz |
| prov:wasDerivedFrom |
wikipedia-en:Roxadustat?oldid=1119603687&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Roxadustat.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Roxadustat |
| is dbo:wikiPageRedirects of |
dbr:C19H16N2O5 dbr:Evrenzo dbr:FG-4592 |
| is dbo:wikiPageWikiLink of |
dbr:Hypoxia-inducible_factor dbr:Simona_Halep dbr:C19H16N2O5 dbr:HIF_prolyl-hydroxylase_inhibitor dbr:Daprodustat dbr:Drone_Hopper–Androni_Giocattoli dbr:ATC_code_B03 dbr:Evrenzo dbr:FG-4592 dbr:Molidustat dbr:Vadadustat |
| is foaf:primaryTopic of |
wikipedia-en:Roxadustat |
